Back to Faculty
Co-Chair

Ola Landgren

MD, PhD
Professor of Medicine, Chief of Myeloma Division & Institute
Sylvester Myeloma Institute, Sylvester Comprehensive Cancer Center, University of Miami

C. Ola Landgren is an MD/PhD Hematology/Oncology specialist with almost 30 years of leadership experience in translational cancer medicine. Over the past two decades, he has served as the leader for large programs at the National Cancer Institute/National Institutes of Health (NCI/NIH), Memorial Sloan Kettering Cancer Center (MSKCC), and University of Miami/Sylvester Comprehensive Cancer Center (UM/SCCC). Currently, he is a Professor of Medicine, Leader of the Translational & Clinical Oncology program, Chief of the Division of Myeloma, and Director of the Myeloma Research Institute at UM/SCCC. Before joining UM/SCCC in 2020, he served as Chief of the Myeloma Service at MSKCC and was Professor Medicine at Cornell Medical College from 2014 to 2020. Prior to that, he served as Senior Investigator and Chief of the Multiple Myeloma Section at the Intramural Program of the NCI/NIH from 2004 to 2014. Prior to joining NCI/NIH, he earned his MD and PhD at Karolinska Institute in Stockholm, Sweden. Throughout his career, his clinical and scientific focus has been on the development of novel treatment strategies for patients with myeloma, partnered with molecular profiling and development of technologies for minimal residual disease (MRD) assessment: targeted detection/intervention to prevent, find, and treat. He has published over 450 peer-reviewed articles in high-impact journals, including Nature Communications, Nature Medicine, Blood, Lancet, JAMA, JCO, and New England Journal of Medicine. Numerous times, he has chaired sessions and presented data at international conferences including ASH, EHA, and ASCO. He is a member of American Society of Clinical Investigation (ASCI).

2027 Sessions

MRD in 2027: From Clinical Trial Endpoint to Clinical Decision Tool

Speaker

Sunday, February 07 11:50–12:10 PM
Room King Ballroom 3
Co-Chair

Ola Landgren

MD, PhD
Professor of Medicine, Chief of Myeloma Division & Institute
Sylvester Myeloma Institute, Sylvester Comprehensive Cancer Center, University of Miami

C. Ola Landgren is an MD/PhD Hematology/Oncology specialist with almost 30 years of leadership experience in translational cancer medicine. Over the past two decades, he has served as the leader for large programs at the National Cancer Institute/National Institutes of Health (NCI/NIH), Memorial Sloan Kettering Cancer Center (MSKCC), and University of Miami/Sylvester Comprehensive Cancer Center (UM/SCCC). Currently, he is a Professor of Medicine, Leader of the Translational & Clinical Oncology program, Chief of the Division of Myeloma, and Director of the Myeloma Research Institute at UM/SCCC. Before joining UM/SCCC in 2020, he served as Chief of the Myeloma Service at MSKCC and was Professor Medicine at Cornell Medical College from 2014 to 2020. Prior to that, he served as Senior Investigator and Chief of the Multiple Myeloma Section at the Intramural Program of the NCI/NIH from 2004 to 2014. Prior to joining NCI/NIH, he earned his MD and PhD at Karolinska Institute in Stockholm, Sweden. Throughout his career, his clinical and scientific focus has been on the development of novel treatment strategies for patients with myeloma, partnered with molecular profiling and development of technologies for minimal residual disease (MRD) assessment: targeted detection/intervention to prevent, find, and treat. He has published over 450 peer-reviewed articles in high-impact journals, including Nature Communications, Nature Medicine, Blood, Lancet, JAMA, JCO, and New England Journal of Medicine. Numerous times, he has chaired sessions and presented data at international conferences including ASH, EHA, and ASCO. He is a member of American Society of Clinical Investigation (ASCI).
Back to top